We are live on ! Find out more
IBT

International Biotechnology Trust Portfolio holdings

AUM $297M
1-Year Est. Return 17.25%
This Fund
S&P 500
This Quarter Est. Return
-7.62%
1 Year Est. Return
+17.25%
3 Year Est. Return
+11.14%
5 Year Est. Return
+79.35%
10 Year Est. Return
–
AUM
$297M
AUM Growth
-$31.7M
Cap. Flow
-$5.36M
Cap. Flow %
-1.8%
Top 10 Hldgs %
47.78%
Holding
70
New
9
Increased
18
Reduced
13
Closed
5

Top Buys

Rank Stock Value
1
QURE icon
uniQure
QURE
+$11M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$8.45M
3
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$8.21M
4
BIIB icon
Biogen
BIIB
+$7.81M
5
GILD icon
Gilead Sciences
GILD
+$6.85M

Top Sells

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$14.3M
2
APLS
Apellis Pharmaceuticals
APLS
+$11.8M
3
AMGN icon
Amgen
AMGN
+$9.48M
4
HRMY icon
Harmony Biosciences
HRMY
+$8.89M
5
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$8.55M

Sector Composition

Rank Sector Weight
1 Healthcare 100%

No holdings matched the selected filter criteria.

1 2 3

Similar funds

DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
DT
Daniels + Tansey Wilmington, Delaware $289M AUM 18.06% 1-Year Est. Return
3LCM
3D/L Capital Management Hartford, Connecticut $308M AUM 13.67% 1-Year Est. Return
TFA
Triad Financial Advisors Greensboro, North Carolina $284M AUM 14.95% 1-Year Est. Return
SFG
Steward Financial Group Colleyville, Texas $315M AUM 13.78% 1-Year Est. Return
AEPLI
AH Equity Partners LSV I Menlo Park, California $315M AUM 9.31% 1-Year Est. Return
CC
Chanos & Company New York $318M AUM 4.62% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

International Biotechnology Trust's Q3 2023 Portfolio in Review

As of Q3 2023, International Biotechnology Trust held 70 positions worth $297M, down 9.6% from $329M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

International Biotechnology Trust's Q3 2023 filing shows 9 new, 18 increased, 13 reduced and 5 closed positions. Its largest new stake was CRISPR Therapeutics: 63,000 shares worth $2.86M. The largest sale was Regeneron Pharmaceuticals, an estimated $14.3M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • International Biotechnology Trust's largest Q3 2023 buy was CRISPR Therapeutics: 63,000 shares worth $2.86M.
  • International Biotechnology Trust added most to uniQure in Q3 2023, an estimated $11M increase.
  • International Biotechnology Trust's biggest Q3 2023 reduction was Regeneron Pharmaceuticals, cutting an estimated $14.3M.
  • International Biotechnology Trust fully exited Apellis Pharmaceuticals in Q3 2023, selling an estimated $11.8M.
  • International Biotechnology Trust's ten largest holdings make up 48% of its $297M portfolio in Q3 2023.
  • International Biotechnology Trust opened 9 new positions and closed 5 in Q3 2023.
  • International Biotechnology Trust's portfolio value fell 9.6% quarter-over-quarter to $297M.

Based on International Biotechnology Trust's 13F filing for Q3 2023, filed 14 Nov 2023.